Skip to main content
. 2015 Oct 27;7(2):1262–1275. doi: 10.18632/oncotarget.6014

Figure 2. Effects of a selective leptin receptor antagonist on breast cancer stem cell activity.

Figure 2

MFE evaluated in MCF-7-M1 and MCF-7-M2 (A) and in MDA-MB-231-M1 and MDA-MB-231-M2 (B) treated with CAF-CM and Adipo-CM with/without peptide LDFI (1 μg/ml). The values represent the means ± s.d. of three different experiments each performed in triplicate. *p < 0.05.